Get the Stockscreener App
46.88
1.62%
-0.77
After Hours:
46.88
Qiagen Nv stock is traded at $46.88, with a volume of 1.98M.
It is down -1.62% in the last 24 hours and down -9.34% over the past month.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
See More
Previous Close:
$47.65
Open:
$47.75
24h Volume:
1.98M
Relative Volume:
0.95
Market Cap:
$9.66B
Revenue:
$2.09B
Net Income/Loss:
$424.88M
P/E Ratio:
22.94
EPS:
2.0439
Net Cash Flow:
$447.20M
1W Performance:
-3.58%
1M Performance:
-9.34%
6M Performance:
-0.34%
1Y Performance:
+23.96%
1-Day Range:
$46.71
$47.98
1-Week Range:
$46.71
$49.86
52-Week Range:
$37.92
$57.81
Qiagen Nv Stock (QGEN) Company Profile
Compare QGEN vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QGEN
Qiagen Nv
|
46.88 | 9.82B | 2.09B | 424.88M | 447.20M | 2.0439 |
|
TMO
Thermo Fisher Scientific Inc
|
512.69 | 190.90B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
204.73 | 144.26B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
648.70 | 50.60B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
120.54 | 33.67B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
319.04 | 30.62B | 3.17B | 642.63M | 516.49M | 10.77 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-22-26 | Downgrade | Deutsche Bank | Buy → Hold |
| Dec-11-25 | Downgrade | Citigroup | Buy → Neutral |
| Jun-24-25 | Initiated | Barclays | Overweight |
| Apr-04-25 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Feb-19-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-06-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-10-24 | Upgrade | Jefferies | Hold → Buy |
| Oct-17-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jun-27-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Dec-07-23 | Upgrade | Goldman | Neutral → Buy |
| Sep-12-23 | Initiated | Robert W. Baird | Outperform |
| May-23-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-18-22 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-18-22 | Upgrade | DZ Bank | Hold → Buy |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Oct-14-21 | Initiated | Redburn | Buy |
| Jul-14-21 | Downgrade | Kepler | Buy → Hold |
| Jun-03-21 | Initiated | Goldman | Neutral |
| Oct-06-20 | Resumed | BofA Securities | Buy |
| Sep-28-20 | Upgrade | Kepler | Hold → Buy |
| Aug-24-20 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-20 | Resumed | JP Morgan | Overweight |
| Aug-17-20 | Upgrade | Berenberg | Hold → Buy |
| Aug-14-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Aug-14-20 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Mar-04-20 | Downgrade | Berenberg | Buy → Hold |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Dec-26-19 | Resumed | BofA/Merrill | Underperform |
| Nov-15-19 | Initiated | Stifel | Hold |
| Nov-14-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-14-19 | Upgrade | JP Morgan | Underweight → Overweight |
| Nov-14-19 | Upgrade | Kepler | Reduce → Hold |
| Oct-17-19 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Oct-09-19 | Downgrade | Kepler | Hold → Reduce |
| Oct-08-19 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-08-19 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-08-19 | Downgrade | JP Morgan | Neutral → Underweight |
View All
Qiagen Nv Stock (QGEN) Latest News
Qiagen Reports Restricted Stock Unit Grant to Supervisory Board Member - The Globe and Mail
Qiagen discloses RSU vesting and share settlement for board member Eva Pisa - The Globe and Mail
Qiagen Reports Higher Stake by Massachusetts Financial Services in Voting Rights Disclosure - TipRanks
PTA-NVR: QIAGEN N.V.: Total Voting Rights Announcement according to Article 41 of the WpHG - TradingView
Total Voting Rights Announcement according to Article 41 of the WpHG - TradingView
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - TradingView
Qiagen N.V. (NYSE:QGEN) Sees Significant Growth in Short Interest - MarketBeat
Qiagen Discloses Executive Equity Award Vesting Under Long-Term Incentive Plan - TipRanks
QIAGEN discloses equity award transaction by CFO Roland Sackers - TipRanks
QIAGEN Reports Supervisory Board Member’s Restricted Stock Unit Release - TipRanks
Qiagen Discloses Manager’s Restricted Stock Unit Vesting and Share Settlement - TipRanks
QIAGEN reports executive equity award vesting under MAR disclosure rules - TipRanks
Qiagen reports executive performance stock unit release and net share settlement - TipRanks
PTA-DD: QIAGEN N.V.: Managers' transactions announcement according to article 19 MAR - TradingView
Managers' transactions announcement according to article 19 MAR - TradingView
Qiagen N.V. (QGEN) Presents at Morgan Stanley European Healthcare ConferenceSlideshow - Seeking Alpha
Intech Investment Management LLC Invests $3.27 Million in Qiagen N.V. $QGEN - MarketBeat
Qiagen CEO says working with advisers on strategic review (QGEN:NYSE) - Seeking Alpha
Qiagen NV (QGEN) Trading Down 3.11% on Mar 2 - GuruFocus
QIAGEN engages advisors to review strategic alternatives - StreetInsider
getLinesFromResByArray error: size == 0 How Qiagen N.V. stock performs in rate cut cyclesJuly 2025 Outlook & Safe Entry Point Identification - mfd.ru
Qiagen N.V. (QGEN) Stock Report: Potential 10.91% Upside With Strong Buy Ratings - DirectorsTalk Interviews
JPMorgan Chase & Co. Sells 512,299 Shares of Qiagen N.V. $QGEN - MarketBeat
QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - Pressetext
Surge in Options Trading Volume for nLight and Qiagen - Intellectia AI
Goldman Sachs Discloses 3.11% Stake in Qiagen via AFM Filing - TipRanks
Release according to Article 40, Section 1 of the WpHG - TradingView
Is Qiagen N.V. in a long term uptrendRate Hike & Daily Market Momentum Tracking - mfd.ru
Vanguard Group Inc. Raises Holdings in Qiagen N.V. $QGEN - MarketBeat
Zacks Research Issues Negative Outlook for Qiagen Earnings - MarketBeat
Total non-current assets of QIAGEN NV – XETR:QIA - TradingView
QGEN Should I Buy - Intellectia AI
Traders Purchase Large Volume of Call Options on Qiagen (NYSE:QGEN) - MarketBeat
Qiagen NV at Citi Global Healthcare Conference Transcript - GuruFocus
Qiagen N.V. (QGEN) Stock Analysis: Exploring a 13.71% Upside Potential in the Diagnostics & Research Sector - DirectorsTalk Interviews
Big Money Moves: Can Qiagen NV ride the EV wave2025 Sector Review & Momentum Based Trading Ideas - baoquankhu1.vn
Contrasting Qiagen (NYSE:QGEN) & Dermata Therapeutics (NASDAQ:DRMA) - Defense World
Jefferies Maintains Qiagen NV(QGEN.US) With Buy Rating, Maintains Target Price $59 - 富途牛牛
MACD Signal: Can Qiagen NV sustain its profitabilityQuarterly Trade Review & Trade Opportunity Analysis Reports - baoquankhu1.vn
Qiagen (NYSE:QGEN) Rating Increased to Buy at Wall Street Zen - MarketBeat
Trend Recap: Should I average down on Qiagen NV stock2025 Retail Activity & Verified Swing Trading Watchlists - baoquankhu1.vn
MFS New Discovery Series's Qiagen NV(QGEN) Holding History - GuruFocus
QIAGEN NV : Barclays gives a Buy rating - marketscreener.com
Qiagen discloses executive share-based compensation transaction - The Globe and Mail
BlackRock Discloses 10.68% Capital Interest and 11.8% Voting Stake in Qiagen - The Globe and Mail
Qiagen N.V.: Why This Quiet Biotech Stock Just Got Loud for US Investors - AD HOC NEWS
Traders Purchase High Volume of Put Options on Qiagen (NYSE:QGEN) - MarketBeat
New Evercode v4 lets labs profile 5M cells, recover 75% more - Stock Titan
Stifel Maintains Qiagen NV(QGEN.US) With Hold Rating, Raises Target Price to $50 - 富途牛牛
Statutory Profit Doesn't Reflect How Good Qiagen's (NYSE:QGEN) Earnings Are - Yahoo Finance
Qiagen NV (QGEN) Shares Down 3.25% on Feb 17 - GuruFocus
Qiagen Nv Stock (QGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
0.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):